
An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds. The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2 gliomas compared to placebo, nearly 28 months versus 11 months, according to results presented Sunday at the American Society of Clinical Oncology (ASCO)… read on > read on >